<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04298840</url>
  </required_header>
  <id_info>
    <org_study_id>2019-997</org_study_id>
    <nct_id>NCT04298840</nct_id>
  </id_info>
  <brief_title>Influence of Creatine Monohydrate Supplementation on Androgens and Global Hair Assessments</brief_title>
  <official_title>Influence of Creatine Monohydrate Supplementation on Androgens and Global Hair Assessments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Tech University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Legion Athletics, Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Texas Tech University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blind, placebo-controlled trial examining the effects of
      creatine monohydrate supplementation on androgens and hair loss in free-living adult males.
      Participants will complete 6 months of supplementation of 5 grams per day of creatine
      monohydrate while following their normal lifestyle practices. At baseline and six months
      after study initiation, participants will complete laboratory assessments. These assessments
      will include a standard blood draw for evaluation of total testosterone (T), free T,
      dihydrotestosterone (DHT), and DHT:T ratios in the blood, as well as global photography and
      questionnaires to evaluate hair loss. This study will examine the claim that creatine
      increases DHT concentrations and and DHT:T ratio, as well as provide novel data regarding
      whether creatine promotes hair loss.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized to receive creatine monohydrate or placebo for daily consumption during the study period.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dihydrotestosterone</measure>
    <time_frame>6 months</time_frame>
    <description>Blood concentration of dihydrotestosterone.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dihydrotestosterone-to-Testosterone Ratio 1</measure>
    <time_frame>6 months</time_frame>
    <description>Ratio of dihydrotestosterone to total testosterone in the blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dihydrotestosterone-to-Testosterone Ratio 2</measure>
    <time_frame>6 months</time_frame>
    <description>Ratio of dihydrotestosterone to free testosterone in the blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Testosterone</measure>
    <time_frame>6 months</time_frame>
    <description>Total testosterone in the blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Free Testosterone</measure>
    <time_frame>6 months</time_frame>
    <description>Free testosterone in the blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Global Hair Assessments</measure>
    <time_frame>6 months</time_frame>
    <description>Subjectively scored assessment of changes in hair properties from baseline to the end of the intervention. Assessor will be a blinded expert.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Self-Reported Hair Assessments</measure>
    <time_frame>6 months</time_frame>
    <description>Survey allowing for participant-reported changes in hair properties as a result of the intervention.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Dihydrotestosterone</condition>
  <condition>Testosterone</condition>
  <condition>Hair Loss</condition>
  <arm_group>
    <arm_group_label>Creatine Monohydrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Creatine Monohydrate Supplementation</intervention_name>
    <description>Participants in the creatine monohydrate supplementation arm will consume 5 grams per day of creatine monohydrate.</description>
    <arm_group_label>Creatine Monohydrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo Supplementation</intervention_name>
    <description>Participants in the placebo supplementation arm will consume 5 grams per day of maltodextrin placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male between the ages of 18 and 35

          -  Weight of at least 110 pounds

          -  Generally healthy (defined as an absence of a disease or medical condition which could
             potentially be negatively influenced by study participation or confound study results)

          -  Low levels of habitual creatine consumption, defined as consuming an average of &lt;10
             g/week of creatine from all supplemental sources within the three months prior to
             study initiation

          -  Willingness to report to baseline and final assessments with a similar haircut (i.e.
             willingness to replicate baseline haircut prior final assessment, to the best of his
             ability) and one that allows for evaluation of hair growth patterns (e.g., not a
             completely shaved head that disallows visualization of the hairline)

          -  Willingness to adhere to the supplementation protocol for the duration of the study
             (i.e., 6 months of daily supplementation with 5 grams per day of creatine monohydrate
             or placebo) and abstain from additional creatine supplement ingestion during this
             time.

          -  Willingness to abstain from any treatments related to hair loss or hair growth for the
             duration of the study

          -  Willingness to maintain normal practices regarding hair products (i.e. continue to use
             regular shampoo, conditioner, and other products over the duration of the study and
             abstain from switching products during the study if at all possible)

        Exclusion Criteria:

          -  Failing to meet any of the aforementioned inclusion criteria

          -  Presence of pacemaker or any electrical device (due to electrical currents
             administered by bioimpedance devices used to assess body composition)

          -  Individual currently participates in any type of hair loss treatment or procedure or
             has undergone any such treatment or procedure within the last 12 months
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grant M Tinsley, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Tech University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Grant M Tinsley, PhD</last_name>
    <phone>8068345895</phone>
    <email>grant.tinsley@ttu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Kinesiology &amp; Sport Management</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>van der Merwe J, Brooks NE, Myburgh KH. Three weeks of creatine monohydrate supplementation affects dihydrotestosterone to testosterone ratio in college-aged rugby players. Clin J Sport Med. 2009 Sep;19(5):399-404. doi: 10.1097/JSM.0b013e3181b8b52f.</citation>
    <PMID>19741313</PMID>
  </reference>
  <reference>
    <citation>Kreider RB, Kalman DS, Antonio J, Ziegenfuss TN, Wildman R, Collins R, Candow DG, Kleiner SM, Almada AL, Lopez HL. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. J Int Soc Sports Nutr. 2017 Jun 13;14:18. doi: 10.1186/s12970-017-0173-z. eCollection 2017. Review.</citation>
    <PMID>28615996</PMID>
  </reference>
  <reference>
    <citation>Kaufman KD. Androgens and alopecia. Mol Cell Endocrinol. 2002 Dec 30;198(1-2):89-95. Review.</citation>
    <PMID>12573818</PMID>
  </reference>
  <reference>
    <citation>Tr√ºeb RM. Molecular mechanisms of androgenetic alopecia. Exp Gerontol. 2002 Aug-Sep;37(8-9):981-90. Review.</citation>
    <PMID>12213548</PMID>
  </reference>
  <reference>
    <citation>Bang HJ, Yang YJ, Lho DS, Lee WY, Sim WY, Chung BC. Comparative studies on level of androgens in hair and plasma with premature male-pattern baldness. J Dermatol Sci. 2004 Feb;34(1):11-6.</citation>
    <PMID>14757277</PMID>
  </reference>
  <reference>
    <citation>Olsen EA, Whiting DA, Savin R, Rodgers A, Johnson-Levonas AO, Round E, Rotonda J, Kaufman KD; Male Pattern Hair Loss Study Group. Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo. J Am Acad Dermatol. 2012 Sep;67(3):379-86. doi: 10.1016/j.jaad.2011.10.027. Epub 2012 Feb 9.</citation>
    <PMID>22325459</PMID>
  </reference>
  <reference>
    <citation>Van Neste MD. Assessment of hair loss: clinical relevance of hair growth evaluation methods. Clin Exp Dermatol. 2002 Jul;27(5):358-65. Review.</citation>
    <PMID>12190635</PMID>
  </reference>
  <reference>
    <citation>Ashique K, Kaliyadan F. Clinical photography for trichology practice: tips and tricks. Int J Trichology. 2011 Jan;3(1):7-13. doi: 10.4103/0974-7753.82118.</citation>
    <PMID>21769229</PMID>
  </reference>
  <reference>
    <citation>Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975 Nov;68(11):1359-65.</citation>
    <PMID>1188424</PMID>
  </reference>
  <reference>
    <citation>Gupta M, Mysore V. Classifications of Patterned Hair Loss: A Review. J Cutan Aesthet Surg. 2016 Jan-Mar;9(1):3-12. doi: 10.4103/0974-2077.178536. Review.</citation>
    <PMID>27081243</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 4, 2020</study_first_submitted>
  <study_first_submitted_qc>March 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2020</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

